February 2023
Unified Airway Disease
Devyani Lal, Angela M. Donaldson and David W. Jang, Editors
Nearly fifteen years later, advances in our understanding of airway inflammation have further refined the concept of the unified airway and have led to more targeted medical therapies. With a greater understanding of type 2 inflammation, we have seen the development and widespread use of biologics for the treatment of nasal polyps and asthma. We have also seen the impact of translational medicine on cystic fibrosis patients. The advent of CFTR modulators has transformed the way we manage the unified airway and has improved the quality of life and morbidity of these patients. With these new advances, close collaboration between otolaryngologists, allergists, pulmonologists, and other specialists has become critical for patient care.